Influenza Clinical Trial
Official title:
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
NCT number | NCT00764790 |
Other study ID # | 111751 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | October 1, 2008 |
Est. completion date | June 1, 2009 |
Verified date | October 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
Status | Completed |
Enrollment | 3317 |
Est. completion date | June 1, 2009 |
Est. primary completion date | March 5, 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 35 Months |
Eligibility |
Inclusion Criteria: - A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable. - Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol. - Written informed consent obtained from the subject's parent/guardian. Exclusion Criteria: - Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion. - History of hypersensitivity to any vaccine. - History of allergy or reactions likely to be exacerbated by any component of the vaccine. - Acute disease at the time of enrolment. - History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine. - Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season. - Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | GSK Investigational Site | Pokfulam | |
Hong Kong | GSK Investigational Site | Shatin | |
Mexico | GSK Investigational Site | Mexico | |
Mexico | GSK Investigational Site | Mexico city | |
Taiwan | GSK Investigational Site | Taipei | |
Taiwan | GSK Investigational Site | Taipei | |
Thailand | GSK Investigational Site | Bangkok | |
United States | GSK Investigational Site | Arkansas City | Kansas |
United States | GSK Investigational Site | Austin | Texas |
United States | GSK Investigational Site | Austintown | Ohio |
United States | GSK Investigational Site | Bardstown | Kentucky |
United States | GSK Investigational Site | Benton | Arkansas |
United States | GSK Investigational Site | Birmingham | Alabama |
United States | GSK Investigational Site | Birmingham | Alabama |
United States | GSK Investigational Site | Boone | North Carolina |
United States | GSK Investigational Site | Bossier City | Louisiana |
United States | GSK Investigational Site | Bountiful | Utah |
United States | GSK Investigational Site | Burke | Virginia |
United States | GSK Investigational Site | Cary | North Carolina |
United States | GSK Investigational Site | Charleston | South Carolina |
United States | GSK Investigational Site | Cincinnati | Ohio |
United States | GSK Investigational Site | Clarksville | Tennessee |
United States | GSK Investigational Site | Cleveland | Ohio |
United States | GSK Investigational Site | Conway | Arkansas |
United States | GSK Investigational Site | Cortland | New York |
United States | GSK Investigational Site | Dayton | Ohio |
United States | GSK Investigational Site | DeKalb | Illinois |
United States | GSK Investigational Site | Dothan | Alabama |
United States | GSK Investigational Site | Erie | Pennsylvania |
United States | GSK Investigational Site | Fargo | North Dakota |
United States | GSK Investigational Site | Fayetteville | Arkansas |
United States | GSK Investigational Site | Fort Worth | Texas |
United States | GSK Investigational Site | Greenville | Pennsylvania |
United States | GSK Investigational Site | Gresham | Oregon |
United States | GSK Investigational Site | Henderson | Nevada |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Huntington Beach | California |
United States | GSK Investigational Site | Jackson | Tennessee |
United States | GSK Investigational Site | Jonesboro | Arkansas |
United States | GSK Investigational Site | Kingsport | Tennessee |
United States | GSK Investigational Site | Latrobe | Pennsylvania |
United States | GSK Investigational Site | Layton | Utah |
United States | GSK Investigational Site | Little Rock | Arkansas |
United States | GSK Investigational Site | Long Beach | California |
United States | GSK Investigational Site | Longmont | Colorado |
United States | GSK Investigational Site | Louisville | Kentucky |
United States | GSK Investigational Site | Metairie | Louisiana |
United States | GSK Investigational Site | Murray | Utah |
United States | GSK Investigational Site | Nampa | Idaho |
United States | GSK Investigational Site | New Albany | Indiana |
United States | GSK Investigational Site | Newton | Kansas |
United States | GSK Investigational Site | Norwich | Connecticut |
United States | GSK Investigational Site | Omaha | Nebraska |
United States | GSK Investigational Site | Paramount | California |
United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
United States | GSK Investigational Site | Provo | Utah |
United States | GSK Investigational Site | Raleigh | North Carolina |
United States | GSK Investigational Site | Roy | Utah |
United States | GSK Investigational Site | Sacramento | California |
United States | GSK Investigational Site | Saint Louis | Missouri |
United States | GSK Investigational Site | Saint Paul | Minnesota |
United States | GSK Investigational Site | San Angelo | Texas |
United States | GSK Investigational Site | San Francisco | California |
United States | GSK Investigational Site | South Jordan | Utah |
United States | GSK Investigational Site | Stevensville | Michigan |
United States | GSK Investigational Site | Uniontown | Pennsylvania |
United States | GSK Investigational Site | West Covina | California |
United States | GSK Investigational Site | Wexford | Pennsylvania |
United States | GSK Investigational Site | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States, Hong Kong, Mexico, Taiwan, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains | GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST) | |
Primary | Number of Subjects Who Seroconverted | Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer = 1:40, or a pre-vaccination titer = 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56 | |
Secondary | Number of Seroprotected Subjects | A seroprotected subject is a subject with a serum anti-HA titer = 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST) | |
Secondary | Seroconversion Factor | Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56 | |
Secondary | Number of Subjects Reporting Solicited Local Symptoms | Solicited local symptoms assessed include pain, redness and swelling. | During a 4-day follow-up period after vaccination | |
Secondary | Number of Subjects Reporting Solicited General Symptoms | Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature. | During a 4-day follow-up period after vaccination | |
Secondary | Number of Subjects Reporting Unsolicited Adverse Events (AE) | An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product | During a 28-day follow-up period after vaccination | |
Secondary | Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD) | An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6) | |
Secondary | Number of Subjects Reporting Rare Serious Events | Rare serious events have an occurrence rate of 1/300 (0.3%). | During the entire study (Day 0 until Month 6) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |